8月19日，艾伯维公司盘中上涨3.04%，报266.765美元/股，成交额8.13亿美元。
消息面上，近期多家华尔街投行密集上调艾伯维目标价：Wolfe将评级上调至"跑赢大盘"并给予300美元目标价，富国银行上调目标价至300美元维持增持，巴克莱上调至300美元，摩根大通上调至285美元，美银上调至276美元。当前FactSet汇总均值目标价已升至约278.73美元，市场共识偏乐观。
管线方面，艾伯维近日在ClinicalTrials平台登记了从荣昌生物引进的PD-1/VEGF双抗RC148全球III期临床试验，头对头对照帕博利珠单抗联合化疗用于一线非小细胞肺癌，标志着该资产进入后期开发阶段，进一步丰富肿瘤管线布局。此外，公司Q2财报营收169.9亿美元、调整后EPS 3.65美元均超预期，核心产品Skyrizi和Rinvoq持续放量，基本面支撑充足。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.